This mutation, identified in a screen of G3 progeny of ENU treated mice for responses to various toll-like receptor ligands, is an A-to-G transition resulting in replacement of valine by alanine at amino acid 327 (V327A), between the second and third leucine-rich domains of the extracellular part of the protein.